Suppr超能文献

冷冻保存的心血管同种异体移植物中残留二甲基亚砜的测定。

Determination of residual dimethylsulfoxide in cryopreserved cardiovascular allografts.

作者信息

Díaz Rodríguez R, Van Hoeck B, De Gelas S, Blancke F, Ngakam R, Bogaerts K, Jashari R

机构信息

European Homograft Bank (EHB), Saint Jean Clinic, Brussels, Belgium.

Laboratoire de Côntrole et d'Analyses (LCA), Brussels, Belgium.

出版信息

Cell Tissue Bank. 2017 Jun;18(2):263-270. doi: 10.1007/s10561-016-9607-0. Epub 2017 Jan 5.

Abstract

Dimethylsulfoxide (DMSO) is a solvent which protects the structure of allografts during the cryopreservation and thawing process. However, several toxic effects of DMSO in patients after transplantation of cryopreserved allografts have been described. The aim of this study is to determine the residual DMSO in the cardiovascular allografts after thawing and preparation of cryopreserved allografts for clinical application following guidelines of the European Pharmacopoeia for DMSO detection. Four types of EHB allografts (aortic valve-AV, pulmonary valve-PV, descending thoracic aorta-DA, and femoral artery-FA) are cryopreserved using as cryoprotecting solution a 10% of DMSO in medium 199. Sampling is carried out after thawing, after DMSO dilution and after delay of 30 min from final dilution (estimated delay until allograft implantation). After progressive thawing in sterile water bath at 37-42 °C (duration of about 20 min), DMSO dilution is carried out by adding consecutively 33, 66 and 200 mL of saline. Finally, tissues are transferred into 200 mL of a new physiologic solution. Allograft samples are analysed for determination of the residual DSMO concentration using a validated Gas Chromatography analysis. Femoral arteries showed the most important DMSO reduction after the estimated delay: 92.97% of decrease in the cryoprotectant final amount while a final reduction of 72.30, 72.04 and 76.29% in DMSO content for AV, PV and DA, was found, respectively. The residual DMSO in the allografts at the moment of implantation represents a final dose of 1.95, 1.06, 1.74 and 0.26 mg kg in AV, PV, DA and FA, respectively, for men, and 2.43, 1.33, 2.17 and 0.33 mg kg for same tissues for women (average weight of 75 kg in men, and 60 kg in women). These results are seriously below the maximum recommended dose of 1 g DMSO kg (Regan et al. in Transfusion 50:2670-2675, 2010) of weight of the patient guaranteeing the safety and quality of allografts.

摘要

二甲基亚砜(DMSO)是一种在冷冻保存和解冻过程中能保护同种异体移植物结构的溶剂。然而,已有文献报道了冷冻保存的同种异体移植物移植后DMSO对患者的几种毒性作用。本研究的目的是按照欧洲药典中DMSO检测指南,测定解冻后心血管同种异体移植物中的残留DMSO,并为临床应用制备冷冻保存的同种异体移植物。四种类型的EHB同种异体移植物(主动脉瓣-AV、肺动脉瓣-PV、胸降主动脉-DA和股动脉-FA)使用含10% DMSO的199培养基作为冷冻保护液进行冷冻保存。在解冻后、DMSO稀释后以及最终稀释后30分钟延迟(估计延迟至同种异体移植物植入)后进行取样。在37-42°C无菌水浴中逐步解冻(持续约20分钟)后,通过依次加入33、66和200 mL生理盐水进行DMSO稀释。最后,将组织转移至200 mL新的生理溶液中。使用经过验证的气相色谱分析法对同种异体移植物样本进行分析,以测定残留DMSO浓度。股动脉在估计延迟后显示出DMSO减少最为显著:冷冻保护剂最终量减少92.97%,而AV、PV和DA的DMSO含量最终分别减少72.30%、72.04%和76.29%。植入时同种异体移植物中的残留DMSO,对于男性,AV、PV、DA和FA中的最终剂量分别为1.95、1.06、1.74和0.26 mg/kg,对于女性,相同组织中的最终剂量分别为2.43、1.33、2.17和0.33 mg/kg(男性平均体重75 kg,女性平均体重60 kg)。这些结果远低于保证同种异体移植物安全性和质量的患者体重最大推荐剂量1 g DMSO/kg(Regan等人,《输血》50:第2670 - 2675页,2010年)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验